Dasatinib and Quercetin: Short-term Simultaneous Administration Yields Senolytic Effect in Humans

Background: The more divisions of cells, the more senescent cells. Senescent cells are one of the most toxic cells in human and animal organisms. When their amount reaches great quantities, it leads to strong manifestation of ageing signs. According to the explanation of the citogenetic centriolar theory of ageing during the division process, the cell's generation reaches ultimate morphogenetic status. As a result, programmed cell death (apoptosis) must be activated, otherwise if the cell does not kill itself it switches to a senescent state. Purpose: Senescent cells cause age-related pathologies. Theoretically, partial elimination of senescent cells must lead to improved life capacity. This hypothesis was confirmed on Ercc1 -/ mice. Periodic simultaneous administration of dasatinib and quercetin in Ercc1 -/ mice led to extension of their healthspan, delaying age-related symptoms and pathologies. We decided to test the senolytic effect of dasatinib and quercetin combination on humans. Study Design: With this purpose the clinical trial was undertaken on 64 male volunteers over the age of 36. To put things into perspective our volunteers were classified into 4 groups with 16 people in each. D+Q group orally administered 50mg of dasatinib with 500 mg of quercetin once a day within 5 days. Methods: To register and to assess changes stemming from the drug compounds the whole trial was complemented with full medical screening and stair ascending test. Results: As a result 50mg of dasatinib along with 500 mg of quercetin demonstrated obvious senolytic effect, it was justified by improved results of stair ascending test and tranquilized state of systolic blood pressure. Such dosage combination of these two compounds is highly probable to be harmless.